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Complementary DNA of human IgE Fce fragment (residues 226~80) lacking the Ce4 domain was expressed 
in Escherichia coli and the product was purified by immunoaffinity chromatography on a monoclonal anti- 
body (El2 0.02)-Affi-Gel 10 column. About 1.8 mg of an apparent dimer and 5.9 mg of a monomer were 
obtained from 65 g E. coli cells with 9.3% recovery. The purified products were found to lack more than 
half of the COOH-terminal portion of the Ce3 domain. The apparent dimer showed high immunological 
specific activity (3.6 x 106 U/mg protein) comparable tothat of natural human IgE when measured by com- 
mercial human IgE determination kits. 
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1. INTRODUCTION 
IgE, which binds to Fce receptors (FceR) on 
basophilic granulocytes and mast cells by the Fce 
portion and sensitizes the cells for antigen-induced 
mediator release, is responsible for various 
hypersensitivity reactions of the immediate type 
[1]. The Fce fragment of IgE, comprising the Ce2, 
Ce3 and Ce4 domains, is sufficient for binding to 
the FceR and inhibits the antigen-induced mediator 
release from cells [2]. 
Recent progress in recombinant DNA 
technology has made it possible to obtain a large 
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amount of the Fce fragment. Gould and co- 
workers [3-5] reported that the recombinant 
human Fce fragment synthesized in E. coli 
assembles spontaneously into a dimer and inhibits 
the sensitization of human lung mast cells in vitro 
and Prausnitz-Kiistner reactions in vivo. We also 
succeeded in purifying the recombinant human Fce 
fragment produced in mouse L cells [6], but did 
not succeed in obtaining the Fce dimer from E. coli 
harbouring the recombinant plasmid, pGETtrp302 
[7]. The Fce fragment synthesized in E. coli did not 
form the dimer, but easily aggregated (unpublish- 
ed). However, we found that Fce fragments yn- 
thesized in E. coli harbouring the recombinant 
plasmid, pGETtrp712 [8], whose cDNA lacked the 
region coding the COOH-terminal 76 amino acid 
residues of the Fce portion, show high im- 
munological activity when measured by commer- 
cial human IgE determination kits. Thus, we have 
attempted to purify the human Fce fragment from 
E. coli, 294/pGETtrp712 and this paper describes 
the purification and characterization of the 
purified protein. 
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Fig. 1. The amino acid sequence predicted from the DNA 
sequence of the insert region of plasmid pGETtrp712. 
Amino acids are expressed in the one-letter code as 
follows: A, alanine; C, cysteine; D, aspartic acid; E, 
glutamic acid; F, phenylalanine; G, glycine; H, 
histidine; I, isoleucine; K, lysine; L, leucine; M, 
methionine; N, asparagine; P, proline; Q, glutamine; R, 
arginine; S, serine; T, threonine; V, valine; W, 
tryptophan; Y, tyrosine. The linker (aspartic acid) of the 
COOH-terminal portion is omitted. ($, it ) Cleavage sites 
predicted from the obtained fragments. 
2. MATERIALS AND METHODS 
Sephacryl S-200 and the PD-10 column were 
purchased from Pharmacia (Tokyo), DEAE- 
Toyopearl 650M from Toyo Soda (Tokyo), Affi- 
Gel 10 and Mr standards for SDS-PAGE from Bio- 
Rad (Richmond, CA), BCA protein assay reagent 
from Pierce (Rockford) and silver stain reagent 
from Wako (Osaka). 
E. coli, 294/pGETtrp712 [8], was cultured in 
M9 medium [7]. The amino acid sequence 
predicted from the DNA sequence of the insert 
region of the plasmid is shown in fig.1. 
The monoclonal anti-human IgE antibody, E l2 
0.02, which recognizes the Ce2 domain [8], was 
purified from ascites fluids and coupled to Affi- 
Gel 10. The detailed procedures were described in 
[9]. 
The concentration of Fce fragment was deter- 
mined by a radioimmunoassay using Pharmacia 
IgE RIA kits (Shionogi, Osaka). Protein was 
estimated by the BCA method [10] using 
crystalline bovine serum albumin as standard. 
SDS-PAGE was carried out as described by Laem- 
mli [11]. The gels were stained with silver stain 
reagent according to the manufacturer's instruc- 
tions. Protein chemical analyses were performed as 
in [6]. 
3. RESULTS 
3.1. Purification of Fce fragment 
All the purification procedures were carried out 
at 5°C. 
(Step 1) Extraction: 65 g of frozen E. coil cells, 
294/pGETtrp712, were mixed with 200 ml of 7 M 
guanidine-HCl/PBS (PBS: 137 mM NaC1, 
2.7 mM KCI, 8.1 mM NazHPO4, 1.5 mM 
KHzPO4; pH 7.4)/20 mM 2-mercaptoethanol (pH 
7.4) and stirred for 4 h. After 267 ml PBS were 
added, the mixture was stirred again for 1 h and 
centrifuged at 30100 x g for 1 h. The supernatant 
was dialyzed against three changes of PBS, 41 
each, every 10 or 14 h. After dialysis, the resulting 
insoluble materials were removed by cen- 
trifugation. 
(Step 2) Immunoaffinity chromatography on 
El2 0.02 Affi-Gel 10: The supernatant (156 ml) 
obtained in step 1 was applied to a monoclonal 
anti-human IgE mouse IgG-Affi-Gel 10 column 
(2.6 × 13.6 cm) equilibrated with PBS at a flow 
rate of 10 ml/h. The column was washed with the 
same buffer at a flow rate of 40 ml/h for 25 h. No 
Fce fragment was detected in the pass-through and 
wash fractions. After the column was washed with 
0.2 M sodium acetate/0.15 M NaCI (pH 7.2), the 
Fce fragment bound to the column was eluted with 
3 M urea/0.2 M sodium acetate/0.15 M NaCI (pH 
5.0). The fractions containing the Fce fragment 
were pooled and dialyzed against one change of 2 1 
PBS for 24 h. After dialysis, the resulting insoluble 
materials were removed by centrifugation. 
(Step 3) Gel filtration chromatography on 
Sephacryl S-200: The supernatant obtained in step 
2 was concentrated using a Diaflo YM-5 mem- 
brane and applied to a Sephacryl S-200 column 
(1.6 x 105 cm) equilibrated with PBS. The Fee 
fragment was eluted with the same buffer at a flow 
rate of 10.8 ml/h. The fractions expected to be a 
dimer and a monomer of the Fee fragment were 
separately pooled (fig.2,D,M). 
(Step 4) Ion-exchange chromatography on 
DEAE-Toyopearl: The pooled fraction D obtained 
in step 3 was dialyzed against one change of 500 ml 
of 10 mM Tris-HCl (pH 8.2) for 24 h and applied 
to a DEAE-Toyopearl column (0.72 x 17 cm) 
equilibrated with the same buffer. The column was 
washed and then a linear NaC1 gradient was ap- 
plied to the column. The gradient was produced by 
307 
Volume 224, number 2 FEBS LETTERS November 1987 
D M 
• 0 .1  
) l l  40  50 
Tube nL ,mber  
I 1 .0  
+ 
% 
_ o 
6o  
Fig.2. Gel-filtration chromatography on a Sephacryl S-200 column. The preparation from step 2 (see table 1 and text) 
was applied to the column (1.6 × 105 cm) equilibrated with PBS. The column was eluted with the same buffer at a flow 
rate of 10.8 ml/h. Fractions of 2.7 ml were collected. ( ) Absorbance at 280 nm and (o) IgE RIA activity. 
continuously adding 100 ml of 10 mM Tris-HCl 
(pH 8.2)/0.3 M NaCI to 100 ml of the 
equilibrating buffer. The proteins were eluted at 
about 110-170 mM NaCI. The fractions showing 
the highest specific activity (eluted at about 
140 mM NaC1) were pooled (hereafter called pD). 
The pooled fraction M obtained in step 3 was also 
applied to the same column and eluted under the 
same conditions. The fractions containing the 
main peak (eluted at about 80 mM NaC1) were 
pooled (hereafter called pM). 
A summary of the purification of the human Fce 
fragment from 65 g of the E. coil cells is given in 
table 1. 
3.2. Purity and molecular forms 
pD and pM were examined by SDS-PAGE to 
check their homogeneity, pM gave almost one 
band that migrated at an apparent Mr of about 
18 000 under non-reducing and reducing conditions 
although a very minor band was present (fig.3, 
lanes 2,4). pD gave a main band that migrated at 
an apparent Mr of 26000 and very heterogeneous 
minor bands that migrated at apparent Mr values 
of 25000-54000 under non-reducing conditions 
(fig.3, lane 1). When reduced with dithiothreitol 
and analyzed by SDS-PAGE, it gave mainly two 
bands that migrated at apparent Mr values of 
20000 and 18000 (fig.3, lane 3). 
3.3. Protein chemical properties 
The NH2-terminal amino acid sequences of pD 
and pM were determined by a gas-phase sequencer. 
At the first step, both pD and pM gave only 
Tab'le i
Summary of purification of recombinant FcE fragment from the extract of E. coli, 
294/pGETtrp712 
Purification step Volume Total IgE RIA Spec. Recovery 
(ml) protein activity act. (%) 
(mg) (10 6 U) (106 U/mg) 
(1) Extract 470 2115 98.7 0.047 (100) 
(2) E12 0.02-Affi-Gel 10 241 31.3 55.4 1.8 56 
(3) Sephacryl S-200 
D 24.7 9.4 19.3 2.1 20 
M 22.3 9.8 3.7 0.38 3.7 
(4) DEAE-Toyopearl 650M 
pD 17.2 1.8 6.5 3.6 6.6 
pM 19.6 5.9 2.7 0.46 2.7 
65 g of E. coli cells were used for purification 
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Fig.3. SDS-PAGE of the purified dimer and monomer 
fractions. SDS-PAGE was carried out in 12.5% 
acrylamide slab gel. pD (lanes 1,3) and pM (lanes 2,4) 
(see table 1 and text) were treated in a boiling water bath 
for 5 min in the absence (lanes 1,2) and presence (lanes 
3,4) of 2% dithiothreitol. Migration of Mr markers is 
shown on the right. 
methionine (recovery 29 and 40%, respectively) 
and the amino acid sequences up to position 15 
were consistent with those deduced from the DNA 
sequence. The COOH-terminal amino acid of pD 
and pM was analyzed by hydrazinolysis and only 
alanine was detected with 23 and 28% recovery, 
respectively. These results and the Mr values 
estimated from SDS-PAGE suggested that our 
preparations deleted the COOH-terminal portion. 
The species of Mr 20000 and 18000 may be ter- 
minated at the position shown by the single and 
double arrows, respectively, in fig.1. The amino 
acid compositions were consistent with those 
4. DISCUSSION 
The COOH-terminal portion was deleted from 
recombinant Fce fragments produced in and 
purified from E. coli, 294/pGETtrp712. We chose 
guanidine-HC1, which decreases the proteolytic ac- 
tivity, to extract he peptide from E. coli. For ex- 
ample, human recombinant -r-interferon was 
obtained as the intact molecule from E. coli when 
guanidine-HCl was used for extraction but not 
when other methods were used [13]. Nevertheless, 
we could not obtain the intact molecule. Since our 
purpose is to obtain the small fragment having 
binding activity to FceR, no further efforts to ob- 
tain the intact molecule were made. The predicted 
cleavage sites are shown in fig.1. It is unknown 
why two kinds of fragment were obtained from pD 
and only one fragment from pM under reducing 
conditions. 
The Fce fragment (Ce2-Ce4 domains) synthe- 
sized in E. coli, 294/pGETtrp302 easily formed ag- 
gregates, and a stable monomer or dimer having 
high reactivity against anti-human IgE antibodies 
has not been obtained in our laboratory (un- 
published). On the other hand, the present results 
show that the Fce fragment lacking the Ce4 domain 
and approximately the terminal half of the Ce3 do- 
main formed only small aggregates; the majority 
of the fragment was stable, pD apparently seemed 
to be a dimer because a main band giving an ap- 
parent Mr of 26000 on SDS-PAGE under non- 
reducing conditions gave two bands of lower Mr 
values of 18000 and 20000 under reducing condi- 
tions. It is curious, however, that the observed Mr 
of the dimer is far smaller than double that of the 
monomer. At the moment, the reason for this is 
unknown. At any rate, it is noteworthy that these 
short molecules retained the ability to bind to anti- 
human IgE antibodies comparable to that of 
natural IgE. These results suggest hat the Ce4 do- 
main and the terminal half of the Ce3 domain play 
an important role in the instability of IgE and Fce. 
Ishizaka et al. [14] observed an increase in the 
number of oligomeric forms during the storage of 
the Fce fragment (Ce2-Ce4 domains) synthesized 
in E. coli at 0°C for several weeks. No polymer or 
aggregates were detected in either pD or pM during 
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storage at 4°C for 1 month (not shown). These 
results support he idea that the Fce fragment lack- 
ing the COOH-terminal portion was more 
favourable than the Fce fragment when E. coli 
were used as host cells to produce active Fce 
molecules. 
It was reported very recently that cDNA con- 
taining parts of the Ce2 and Ce3 domains was ex- 
pressed in E. coli and that the product inhibited 
passive cutaneous anaphylaxis n human skin [15]. 
However, no protein-chemical characterization 
was carried out for the peptide produced in E. coli 
in that report. The specific activity of our pD was 
3.6 × l0  6 U/mg protein (table 1). That of the 
recombinant Fce fragment (Ce2-Ce4 domains) 
produced in and purified from mouse L cells was 
0.96 × 10 6 U/mg protein [6] and that of the L cell 
derived Fce fragment stored at 4°C for 6 months 
was 1.5 X 10 6 U/mg protein (not shown; the con- 
centration of protein was also reestimated by the 
BCA method). The Mr values of pD and L cell 
derived Fce fragment calculated from their amino 
acid compositions are 17830 and 38480 (values as 
monomer), respectively. Therefore, the activity per 
molecule is nearly the same. These results indicate 
that the dimers lacking the Ce4 domain and half of 
the Ce3 domain synthesized in E. coli have full 
binding ability to anti-human IgE antibodies in the 
IgE RIA kits. The biological activity of these 
fragments remains to be compared. 
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